Key result
A male subject exhibited a platelet defect with absent adrenaline-induced aggregation and lack of secondary aggregation to ADP and PAF, but no bleeding tendency due to synergistic agonist responses.
Case Report (n=1)
Describes a specific platelet aggregation defect that does not cause clinical bleeding, likely because multiple subthreshold agonists in vivo can overcome the single-agonist defect.
Answers are grounded in this paper and cite their sources.
May not indicate bleeding risk despite absent adrenaline aggregation; leaves open compensatory roles of synergistic agonists in vivo.
We describe a platelet defect characterised by absence of aggregation to adrenaline and lack of secondary aggregation to ADP and platelet-activating factor (PAF) in a male subject without a significant bleeding tendency. The platelets also exhibited a decreased response to the phorbol ester PMA and to vasopressin polypeptides. We obtained evidence that the defect did not involve the cyclooxygenase pathway and that it was not dependent on altered intraplatelet levels of cyclic AMP (cAMP). Furthermore, adrenaline-stimulated cAMP production was normal. Irreversible aggregation was obtained in response to a combination of two stimuli at subaggregating concentrations. This observation indicates that the lack of a bleeding tendency in this subject may be ascribed to subthreshold concentrations of agonists in vivo overcoming the defect to a single agonist.
No takes yet. Share an insight, caveat, or question.
Anfossi et al. (1991) conducted a case report in Platelet defect (n=1). Platelet defect was evaluated on Platelet aggregation response to various stimuli. A male subject exhibited a platelet defect with absent adrenaline-induced aggregation and lack of secondary aggregation to ADP and PAF, but no bleeding tendency due to synergistic agonist responses.
Synapse has enriched 10 related papers. Consider them for comparative context: